Psychedelic Drugs as Therapeutics: No Illusions About the Challenges
Edward M. Sellers, Deborah B. Leiderman
Clinical Pharmacology & Therapeutics August 24, 2017 DOI: 10.1002/cpt.776 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Psychotomimetic Hallucinogen Illusion Variety cybernetics Pharmacology Artificial intelligence |
| Citations | 27 |
| Key findings | Obtaining approval to market a restricted psychotomimetic agent is formidable. |
Abstract
Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic agent are formidable.
Comparable studies
Other narrative reviews on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| The pharmacology of psilocybin | 2002 | Review | |
| Serotonin research: contributions to understanding psychoses | 2008 | Review | |
| Psychedelics, Meditation, and Self-Consciousness | 2018 | Review | |
| The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | 2018 | Review |
Citations in the library
Cited by 24
- Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology December 25, 2017
- Cessation and reduction in alcohol consumption and misuse after psychedelic use Journal of Psychopharmacology May 14, 2019
- Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions International Review of Psychiatry July 4, 2018
- Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey Frontiers in Psychiatry January 22, 2020
- DARK Classics in Chemical Neuroscience: Psilocybin ACS Chemical Neuroscience June 29, 2018
and 19 more in the library
Cites 4
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psychedelics as Medicines: An Emerging New Paradigm Clinical Pharmacology & Therapeutics November 4, 2016
- Psilocybin: Good Trip or Bad Trip Clinical Pharmacology & Therapeutics May 26, 2017